Agenus (NASDAQ:AGEN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Agenus and Regeneron Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Agenus | 0 | 0 | 3 | 0 | 3.00 |
Regeneron Pharmaceuticals | 0 | 6 | 15 | 1 | 2.77 |
Agenus presently has a consensus target price of $8.00, indicating a potential upside of 153.16%. Regeneron Pharmaceuticals has a consensus target price of $625.8077, indicating a potential upside of 39.26%. Given Agenus' stronger consensus rating and higher probable upside, equities analysts plainly believe Agenus is more favorable than Regeneron Pharmaceuticals.
Valuation and Earnings
This table compares Agenus and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Agenus | $150.05 million | 4.00 | $-107,660,000.00 | ($0.80) | -3.95 |
Regeneron Pharmaceuticals | $7.86 billion | 6.12 | $2.12 billion | $21.47 | 20.93 |
Regeneron Pharmaceuticals has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.
Institutional and Insider Ownership
53.4% of Agenus shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 4.7% of Agenus shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Agenus and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Agenus | -192.56% | N/A | -97.02% |
Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
Summary
Regeneron Pharmaceuticals beats Agenus on 12 of the 15 factors compared between the two stocks.